Cross-kingdom microbial interactions in the gut during inflammatory bowel disease - PubMed
3 hours ago
- #IBD
- #microbial metabolites
- #gut microbiome
- Inflammatory bowel disease (IBD) includes Crohn's disease and ulcerative colitis, characterized by chronic gastrointestinal inflammation.
- Gut microbiome dysbiosis plays a key role in IBD, involving interactions among bacteria, fungi, protozoa, and viruses.
- Microbial metabolites like SCFAs, indoles, and bile acids regulate mucosal immunity and barrier function.
- Disruptions in microbial interactions contribute to chronic inflammation and disease progression in IBD.
- Multi-kingdom therapies such as probiotics, yeast-based treatments, and FMT show promise but face clinical variability challenges.
- Personalized treatment strategies and multi-omics studies are essential for effective IBD management.
- Further research and larger clinical trials are needed to translate findings into clinical practice.